HC Wainwright & Co. Maintains Buy on Arcus Biosciences, Raises Price Target to $45
Arcus Biosciences, Inc.
Arcus Biosciences, Inc. RCUS | 0.00 |
HC Wainwright & Co. analyst Emily Bodnar maintains Arcus Biosciences (NYSE:
RCUS) with a Buy and raises the price target from $32 to $45.